Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185101 | 1.00 | TBXAS1 (0.46) | TBXAS1TAAR1FDPSFPR2GAA | |
| SCHEMBL11456188 | 0.81 | TBXAS1 (0.49) | TBXAS1TAAR1FDPSFPR2GAA | |
| SCHEMBL334040 | 0.80 | TBXAS1 (0.47) | TBXAS1TAAR1FDPSFPR2GAA | |
| SCHEMBL9554662 | 0.80 | TBXAS1 (0.47) | TBXAS1TAAR1FDPSFPR2GAA | |
| SCHEMBL24834446 | 0.79 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2ALOX15 | |
| SCHEMBL781663 | 0.79 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2ALOX15 | |
| SCHEMBL3838965 | 0.79 | GRIA2 (0.51) | TBXAS1TAAR1FDPSFPR2ALOX15 | |
| SCHEMBL30426597 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL11090438 | 0.76 | GRIA1 (0.49) | TBXAS1TAAR1FDPSFPR2ALOX15 | |
| SCHEMBL4688922 | 0.75 | TBXAS1 (0.43) | TBXAS1TAAR1FDPSFPR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | TBXAS1 686/4885TAAR1 3245/4885FDPS 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.